Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| ciliated cell | 11 studies | 27% ± 12% | |
| epithelial cell | 5 studies | 31% ± 10% | |
| retinal cone cell | 5 studies | 35% ± 16% | |
| retinal rod cell | 5 studies | 23% ± 5% | |
| B cell | 3 studies | 20% ± 5% | |
| GABAergic neuron | 3 studies | 28% ± 9% | |
| natural killer cell | 3 studies | 16% ± 0% | |
| basal cell | 3 studies | 19% ± 3% | |
| goblet cell | 3 studies | 19% ± 1% | |
| astrocyte | 3 studies | 18% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 1614.62 | 1445 / 1445 | 100% | 9.46 | 183 / 183 |
| intestine | 100% | 2139.16 | 966 / 966 | 100% | 12.99 | 527 / 527 |
| liver | 100% | 1812.14 | 226 / 226 | 100% | 10.66 | 406 / 406 |
| ovary | 100% | 2188.21 | 180 / 180 | 100% | 11.20 | 430 / 430 |
| prostate | 100% | 2306.92 | 245 / 245 | 100% | 14.87 | 502 / 502 |
| skin | 100% | 1678.90 | 1809 / 1809 | 100% | 12.72 | 472 / 472 |
| stomach | 100% | 1672.60 | 359 / 359 | 100% | 12.48 | 286 / 286 |
| lung | 100% | 1919.60 | 577 / 578 | 100% | 11.15 | 1155 / 1155 |
| breast | 100% | 1924.20 | 459 / 459 | 100% | 14.37 | 1116 / 1118 |
| bladder | 100% | 1823.33 | 21 / 21 | 100% | 12.65 | 503 / 504 |
| uterus | 100% | 1927.89 | 170 / 170 | 100% | 12.78 | 458 / 459 |
| kidney | 100% | 3083.22 | 89 / 89 | 100% | 13.27 | 899 / 901 |
| brain | 100% | 1505.38 | 2636 / 2642 | 100% | 11.87 | 705 / 705 |
| pancreas | 100% | 1234.32 | 327 / 328 | 100% | 12.17 | 178 / 178 |
| thymus | 100% | 2224.80 | 653 / 653 | 100% | 12.92 | 603 / 605 |
| adrenal gland | 100% | 2204.05 | 258 / 258 | 97% | 8.67 | 224 / 230 |
| adipose | 100% | 1707.58 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 100% | 9.52 | 80 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 20.41 | 29 / 29 |
| peripheral blood | 100% | 2884.40 | 929 / 929 | 0% | 0 | 0 / 0 |
| spleen | 100% | 2658.66 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 11.81 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 3.85 | 1 / 1 |
| blood vessel | 100% | 1541.44 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 100% | 1443.54 | 802 / 803 | 0% | 0 | 0 / 0 |
| heart | 99% | 1072.24 | 851 / 861 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0007165 | Biological process | signal transduction |
| GO_0018105 | Biological process | peptidyl-serine phosphorylation |
| GO_0070373 | Biological process | negative regulation of ERK1 and ERK2 cascade |
| GO_0007519 | Biological process | skeletal muscle tissue development |
| GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0004674 | Molecular function | protein serine/threonine kinase activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0019903 | Molecular function | protein phosphatase binding |
| GO_0005524 | Molecular function | ATP binding |
| Gene name | VRK3 |
| Protein name | VRK serine/threonine kinase 3 Serine/threonine-protein kinase VRK3 (EC 2.7.11.22) (Vaccinia-related kinase 3) |
| Synonyms | |
| Description | FUNCTION: Plays a role in the regulation of the cell cycle by phosphorylating the nuclear envelope protein barrier-to-autointegration factor/BAF that is required for disassembly and reassembly, respectively, of the nuclear envelope during mitosis . Under normal physiological conditions, negatively regulates ERK activity along with VHR/DUSP3 phosphatase in the nucleus, causing timely and transient action of ERK. Stress conditions activate CDK5 which phosphorylates VRK3 to increase VHR phosphatase activity and suppress prolonged ERK activation that causes cell death . For example, upon glutamate induction, promotes nuclear localization of HSP70/HSPA1A to inhibit ERK activation via VHR/DUSP3 phosphatase . . |
| Accessions | ENST00000377011.6 [Q8IV63-3] M0QXV1 ENST00000594092.5 [Q8IV63-2] ENST00000600137.5 ENST00000599342.5 ENST00000316763.8 [Q8IV63-1] M0QZ79 ENST00000601324.1 ENST00000596445.5 ENST00000594090.5 ENST00000600259.5 M0QYG0 M0R025 ENST00000601912.5 M0R164 ENST00000596814.5 M0QX88 M0R3H2 ENST00000596121.5 ENST00000593912.5 ENST00000594948.5 [Q8IV63-1] ENST00000599538.5 [Q8IV63-1] M0R073 ENST00000593919.5 M0QXD7 M0R200 Q8IV63 M0QYA8 ENST00000597215.5 ENST00000601341.5 [Q8IV63-3] |
